eCite Digital Repository

Technology evaluation: MRA, Chugai


Ding, C and Jones, G, Technology evaluation: MRA, Chugai, Current Opinion in Molecular Therapeutics, 5, (1) pp. 64-9. ISSN 1464-8431 (2003) [Professional, Non Refereed Article]


Chugai, the Japanese subsidiary of Roche, is developing a humanized anti-interleukin (IL)-6 receptor monoclonal antibody MRA for the potential treatment of multiple myeloma, rheumatoid arthritis, Crohn's disease and other IL-6-related disorders. MRA is currently undergoing phase II clinical trials for these indications.

Item Details

Item Type:Professional, Non Refereed Article
Research Division:Biomedical and Clinical Sciences
Research Group:Pharmacology and pharmaceutical sciences
Research Field:Clinical pharmacology and therapeutics
Objective Division:Health
Objective Group:Clinical health
Objective Field:Clinical health not elsewhere classified
UTAS Author:Ding, C (Professor Chang-Hai Ding)
UTAS Author:Jones, G (Professor Graeme Jones)
ID Code:28591
Year Published:2003
Web of Science® Times Cited:15
Deposited By:Menzies Centre
Deposited On:2003-08-01
Last Modified:2004-03-15

Repository Staff Only: item control page